The Role of C5a Receptors in Urothelial Carcinomas of the Upper Urinary Tract

The Role of C5a Receptors in Urothelial Carcinomas of the Upper Urinary Tract - C5aRs in UTUC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040748

Enrollment

Registered

2026-06-24

Start date

2026-06-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinomas of the upper urinary tract (UTUC)

Interventions

Group 1: A retrospective study combined with prospective data collection from archived tissue samples and corresponding clinical-pathological data from patients who underwent a (radical) nephrectomy w

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: The study includes patients with urothelial carcinomas of the upper urinary tract who underwent a radical nephrectomy with ureterectomy or a nephrectomy with ureterectomy at the Department of Urology, UKSH Campus Lübeck, between 2010 and 2025, and whose tissue samples are available at the Institute of Pathology, UKSH, Campus Lübeck. Only patients who have signed a broad consent form will be included.

Exclusion criteria

Exclusion criteria: Patients with urothelial carcinomas of the upper urinary tract who underwent surgical treatment between 2010 and 2025 at the Department of Urology, UKSH Campus Lübeck, but did not sign a broad consent form, are excluded.

Design outcomes

Primary

Measure	Time frame
Quantification and comparison of C5aR1 and C5aR2 expression in tumor tissue and corresponding normal tissue from the included patients using immunohistochemical staining and digital image analysis.	—

Secondary

Measure	Time frame
1. Quantification and comparison of immune cell infiltration as a function of the expression of the two receptors using spatial transcriptomics to quantify immune cell populations per patient/region. 2. Correlation of receptor expression (C5aR1/C5aR2) and immune cell infiltration with clinical-pathological parameters using correlation analyses. 3. Analysis of differential gene expression between tumor and normal tissue to investigate the influence of the receptors using spatial transcriptomics with differential expression analysis per tissue region (tumor vs. normal tissue). 4. Identification of active signaling pathways in patients’ tumor samples and analysis of differences depending on receptor expression (C5aR1/C5aR2) using bioinformatic signaling pathway analysis of the spatial transcriptomics data.	—

Measure

Time frame

1. Quantification and comparison of immune cell infiltration as a function of the expression of the two receptors using spatial transcriptomics to quantify immune cell populations per patient/region. 2. Correlation of receptor expression (C5aR1/C5aR2) and immune cell infiltration with clinical-pathological parameters using correlation analyses. 3. Analysis of differential gene expression between tumor and normal tissue to investigate the influence of the receptors using spatial transcriptomics with differential expression analysis per tissue region (tumor vs. normal tissue). 4. Identification of active signaling pathways in patients’ tumor samples and analysis of differences depending on receptor expression (C5aR1/C5aR2) using bioinformatic signaling pathway analysis of the spatial transcriptomics data.

—

Countries

Germany

Contacts

Public ContactLea Sophie Lütje

Klinik für Urologie des UKSH Campus Lübeck

leasophie.luetje@uksh.de045131018780

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026